Eli Lilly looks to extend its winning streak over the broader market to 6 years
0 5 mins 21 hrs


An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. 

Shelby Knowles | Bloomberg | Getty Images

Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street woke up to its massive opportunity in obesity drugs. Six in a row is not out of the question.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *